Member Info for 1DayRodney

Please tell that to the stock/share price 🙄

@ roger65

"no one really wants it yet or can afford it."

This is just your own unsubstantiated and characteristically gloomy speculation.

NICE 'conditional' approval was only received 6mths ago. NHS Trusts just don't move that fast when introducing or procuring new technology. Remember, that's what it is, new technolgy. Each trust has to make its own case.

You don't know which trusts have enquired or at what point of the process any engaged trust currently stands (unless of course you have privileged info!).

I agree, the lack of comms from company and the way things have gone is enormously frustrating but hopefully we will soon receive either a status update or presentation notification for all current and future Genedrive kits and assays.

GLA

I wonder how much last year's AGM vote influenced this board change 🤔

Time for this company to climb out of its nappies and start growing!

Apologies, my post on this thread is @ stocksaint

Why are you talking about yourself in the 3rd person?

Also, and apoligies if I'm mistaken, but I don't recall stephen11 blaming anybody for his "hideous investment decisions" and nor do I believe anyone else here does.

I think his posting is more a comment on your monotonous and combative dogma.

# 'I don't believe this stock will move very'

Why ain't there a bl***dy edit button!🙄

# 'I don't believe this stock'

Seem a very fluffy RNS.

"To this end, our path towards commencing development, and subsequent production, subject to, inter alia, funding, "

"Our next steps include upscaling the testwork to deliver an additional economic study to further explore the project parameters."

No definitive dates or timescales or potential fund raising parameters for Pitombeiras stated.

It hasn't even been confirmed if the 25T test sample proposed previously has even been despatched.

I don't this stock will not move very far based on investee company results alone.

So much potential here but one for the bottom drawer for now...

@Slacker

"The test will be used at Manchester Royal Infirmary and the Manchester Centre for Genomic Medicine, Saint Mary’s Hospital, both part of MFT, over the next six months, to further evaluate performance in the clinical setting."

Now the test can be legally used within a clinical environment in Great Britain, I would say NICE approval, if (or rather when) it comes will probably be after this.

If the golden goose is smiling on us, then it's all bets off..

Oh dear Slacker, you seem so bitter and disappointed at positive news.... strange.

Very positive news.

Well done to all those involved at Genedrive.

The other thing worth noting is David Budd has share options (of which there are several) including one for 1,056,982 shares at a price of 9p which was granted in Apr 2020 (right at the start of Covid) and doesn't expire until Apr 2030.

Would probably shed some light on the 'why aren't the board buying shares' questions for some investors.

Also in my last post, Russ Shaw's figure is only a portion of his salary as he joined part-way through the year, so thus year that figure will be higher.

@Lionel1

Annual Report Dec 2022 (Genedrive website)

http://www.genedriveplc.com/investor-relations/company-reports.php

Exec BOD Remuneration (totals):

David Budd -- £277,116 (salary £238,170)

Russ Shaw -- £58,551

Non-exec BOD Remuneration (totals):

Ian Gilham -- £65,000

Tom Lindsay -- £35,000

Chris Yates -- £35,000

Those committee representatives are from some heavy hitting establishments.

It looks to me that:

* The kit is still being taken seriously. To appoint a committee of that level costs the NHS time and money.

* The data gathering and study must be moving along nicely for there to be a need for a committee to be formed to review said findings.

Of course, none of this guarantees final widespread NICE recommended adoption but it does show positive progress for this particular kit.

The 2nd NICE committee meeting for the Clopidogrel (stroke) assay is also still on for the end of this month but it would be nice to have a general update from GDR on its progress.

As I understand it, it is not a 'financing' deal. TRR are purchasing the royalty from private individuals who presumably held a royalty after financing the original company which B2Gold merged/tookover.

Recent RNS -

"pleased to announce that it has entered into a binding acquisition agreement ("Agreement") with a group of private royalty holders ("Sellers") to acquire a 50% interest in a 2% net smelter royalty (the "Royalty") over the Dandoko Gold Project permit area in western Mali ("Dandoko" or the "Project"), owned by B2Gold Corporation Limited"

Little bit of history.....

https://www.b2gold.com/projects/producing/fekola/#:~:text=The%20Fekola%20Mine%20is%20located,Resources%20Limited%20in%20October%202014.

Don't suppose anyone's spotted 25T of Brazilian dirt bobbing around the South Atlantic anywhere? 🚢

Thought we'd be due an update about now or am I being impatient? 🤷‍♂️

"WHAT DO YOU GUYS THINK OF RIVAL ABDX NEWS TODAY? ANY OPINIONS APPRECIATED?"

My thoughts are it's gonna be easier to spit on a test stick than p!ss on it so well done and good luck.

I suspect that many investors (and maybe even the BOD) are thinking to themselves or out loud on a BB like this one as to why the sp has not moved on from last year despite this year's encouraging developments/acquisitions, debt cost reduction and listing in the USA.

I haven't seen anyone here having direct complaints about either the board, their investments or their strategy - I think all longer term investors understand those.

The recent points on this BB were just items for discussion, after all, that's what BBs are for!

I still remain confidently invested.

Must admit I'm hugely disappointed at this years performance as a longer term investment.

Maybe if there was some form of projection or roadmap towards the first dividend payment (after that's what loyalty companies are all about!) then maybe investors' interest could be rekindled.

At the moment promising jam tomorrow don't cut it when there are many other investment opportunities (or even savings rates) out there in the meanwhile.

Hope those H2 deals mentioned in the latest presentation go through and stop the sp slip!

The AGM voting could be a little eye opener next week (don't forget to vote!).

If any discord is shown towards any of the board members it will be interesting to see the response.

Going on CEO's reaction last year to the shareholders' disappointment when the mining report was released, it could be a bit spicy...